Janux Therapeutics (JANX)
13.17
-0.45 (3.30%)
Upcoming Events
Latest Headlines
Form 4 Janux Therapeutics, Inc. For: Jun 02 Filed by: Doyle Janeen Noel
June 4, 2026 8:00 PM - SEC Filing
Form 144 Janux Therapeutics, Inc. Filed by: Doyle Janeen Noel
June 2, 2026 6:04 PM - SEC Filing
Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC
May 15, 2026 12:39 PM - SEC Filing
Form 4 Janux Therapeutics, Inc. For: May 11 Filed by: Dobek Maria
May 13, 2026 8:00 PM - SEC Filing
Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: STATE STREET CORP
May 12, 2026 11:19 AM - SEC Filing
Janux Therapeutics (JANX) PT Lowered to $60 at Cantor Fitzgerald
May 8, 2026 8:07 AM - StreetInsider
Janux Therapeutics (JANX) PT Lowered to $26 at Piper Sandler
May 8, 2026 7:58 AM - StreetInsider
Janux Therapeutics (JANX) PT Lowered to $58 at Guggenheim
May 8, 2026 7:22 AM - StreetInsider
Janux Therapeutics, Inc. (JANX) Tops Q1 EPS by 18c
May 7, 2026 6:33 PM - StreetInsider
Form 10-Q Janux Therapeutics, Inc. For: Mar 31
May 7, 2026 4:36 PM - SEC Filing
Form 8-K Janux Therapeutics, Inc. For: May 07
May 7, 2026 4:19 PM - SEC Filing
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026 4:01 PM - BizWire
Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: FMR LLC
May 6, 2026 11:24 AM - SEC Filing
Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.
April 29, 2026 5:32 PM - SEC Filing
Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.
April 29, 2026 5:31 PM - SEC Filing
Form 8-K Janux Therapeutics, Inc. For: Apr 28
April 28, 2026 5:02 PM - SEC Filing
Form ARS Janux Therapeutics, Inc. For: Dec 31
April 28, 2026 4:56 PM - SEC Filing
Form DEFA14A Janux Therapeutics, Inc.
April 28, 2026 4:23 PM - SEC Filing
Form DEF 14A Janux Therapeutics, Inc. For: Jun 11
April 28, 2026 4:16 PM - SEC Filing
Janux Therapeutics (JANX) PT Lowered to $24 at BofA Securities
April 28, 2026 1:13 PM - StreetInsider
Janux Therapeutics (JANX) PT Lowered to $28 at Jones Trading
April 28, 2026 1:05 PM - StreetInsider
Janux Therapeutics (JANX) PT Lowered to $45 at Leerink Partners
April 28, 2026 10:50 AM - StreetInsider
Janux Therapeutics discontinues EGFR cancer drug development
April 27, 2026 4:01 PM - StreetInsider
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 27, 2026 4:01 PM - BizWire
H.C. Wainwright Reiterates Buy Rating on Janux Therapeutics (JANX)
April 22, 2026 6:42 AM - StreetInsider
Barclays Double Downgrades Janux Therapeutics (JANX) to Underweight
April 20, 2026 3:59 AM - StreetInsider
Janux starts dosing first patient in JANX014 phase 1 trial
April 16, 2026 4:01 PM - StreetInsider
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
April 16, 2026 4:01 PM - BizWire
UBS Downgrades Janux Therapeutics (JANX) to Neutral
April 15, 2026 2:24 AM - StreetInsider
Form 144 Janux Therapeutics, Inc. Filed by: Meyer Andrew Hollman
April 13, 2026 4:05 PM - SEC Filing
Janux Therapeutics (JANX) PT Lowered to $23 at Evercore ISI
April 10, 2026 3:15 PM - StreetInsider
Jones Trading Assumes Janux Therapeutics (JANX) at Buy
April 6, 2026 4:16 PM - StreetInsider
Form 144 Janux Therapeutics, Inc. Filed by: McIver Zachariah
April 2, 2026 4:02 PM - SEC Filing
Janux receives $35 million milestone payment from Bristol Myers Squibb
April 1, 2026 8:02 AM - StreetInsider
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
April 1, 2026 8:01 AM - BizWire
Full Article List
